Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Stocks That Have It All

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Most Fools are fans of having long-term relationships with their stocks. This lets us thumb our noses at the mostly short-term-focused investors on Wall Street and take advantage of things like time arbitrage and the compounding magic of dividends.

We don't, however, marry our stocks. As much as we may like our stocks, we still need to maintain enough distance that we're able to part ways if something bad happens at the company, other investors are offering us such a high price that it'd be silly not to sell, or ...

We find something better
To be sure, the grass isn't always greener when it comes to investments. Even when it may appear to be somewhat greener, costs like trading fees and taxes may make it not worthwhile to change horses.

But since we don't have an exclusive relationship with the stocks in our portfolio, we can feel free to shop around and see what else is out there, just in case there is a dream floating around that you don't own. For me, that means finding a stock with:

  • A forward price-to-earnings ratio below 14;
  • A dividend above 2.5%;
  • A debt-to-equity ratio below 100%;
  • A return on unlevered net tangible equity (a measure I borrowed from Warren Buffett) above 20%;
  • A business that I understand.

The list that I came up with includes a fair number of stocks that I already own -- AT&T and Abbott Labs, for instance -- but since I'm looking for fair maidens that I'm not already well acquainted with, I removed those from consideration. What follows are three of my favorites from the group.

Raytheon (NYSE: RTN  )
Defense contractors have been blinking on my investment radar for a while now. Passed over by many investors thanks to concerns over the defense budget, many of these stocks have ended up with compelling valuations. Just last month I highlighted that noted value investor Tweedy, Browne had taken up a position in Lockheed Martin (NYSE: LMT  ) .

However, the list of "dream stock" requirements above seriously narrows the number of defense contractors that I have to choose from, and, with a debt-to-equity ratio of 135%, Lockheed doesn't make the cut.

In fact, the only two that did make the list were Raytheon and Northrop Grumman. Choosing between them was tough. On the basis of forward P/E, Northrop was slightly cheaper, though Raytheon's returns on unlevered tangible equity were much better. Debt-to-equity is nearly the same for both companies, as is the dividend yield.

So what tipped the scales in favor of Raytheon? I like the business mix at Raytheon, which is a bit more focused on information and surveillance systems, versus the exposure to big projects like planes and ships at Northrop. And while I don't focus on insider ownership as much as some Fools, I do like the fact that Raytheon's CEO owns $44 million worth of company stock. And finally, the Motley Fool CAPS community gives Raytheon the edge with a four-star rating versus Northrop's three.

Willis Group (NYSE: WSH  )
People- and knowledge-based businesses can be tough because it's difficult to create a competitive moat and there's less opportunity for operating leverage. However, when it's done right, it can end up a virtual empire. I put both Accenture and Goldman Sachs into this camp.

Willis Group is another that I put here. I don't think the phrase "insurance brokerage" conveys the full extent of why I like Willis' business, so I prefer to think of it more as a "risk management consultancy," helping clients navigate the wooly world of insurance and making sure they're covered for the specific risks that they're exposed to.

Willis' stock currently trades at a lower multiple than direct competitors Aon and Marsh & McLennan (NYSE: MMC  ) despite the fact that it's projected to grow faster. However, it's not smack-yourself-to-see-if-it's-real cheap as compared to its historical trading range.

Overall, though, I like Willis' business, its stock is attractively priced, and it pays you a decent dividend. If you liked Raytheon's CEO's ownership stake, then you'll love the $148 million in Willis stock that CEO Joseph Plumeri owns.

AstraZeneca (NYSE: AZN  )
Since I'm a fan of dividends and the first two picks were on the low end in terms of yield, I wanted a bit more payout in the final spot. And big pharma is certainly the place to find that these days.

To be sure, there's a reason for that. Big pharma companies are facing a nasty patent cliff that will slash revenue as big drugs lose their patent protection. Pfizer (NYSE: PFE  ) may be catching the worst of it with the $11 billion Lipitor going off-patent in 2010, but Merck (NYSE: MRK  ) lost $3.6 billion when Cozaar expired last year and faces another big hit when Singulair goes off-patent in 2012. AstraZeneca doesn't get a pass here, either. In 2012, both Atacand and Seroquel lose patent protection. The two produced combined revenue north of $6 billion in 2009.

But the stocks have already been knocked down significantly from the patent-expiration fears and investors have been able to pick up juicy dividends and may also benefit from big buyback programs. As for the future, it's no easier to predict drug approvals for these giants than it is to wager on the biopharma small fries. However, like Willis above, AstraZeneca and the other big pharma companies are largely knowledge-based businesses with a lot of talented scientists putting a lot of irons in the fire. Could it really be that the well will run dry after current drugs go off-patent?

What now?
Whether or not you're ready to buy, I think all three of these stocks deserve to be on your Foolish watchlist. You can add them easily by clicking on Raytheon, Willis Group, and AstraZeneca. Don't have a watchlist yet? Set one up now -- you'll get timely updates and a free copy of the special report "Six Stocks to Watch from David and Tom Gardner."

Accenture and Pfizer are Motley Fool Inside Value selections. The Fool owns shares of Abbott Laboratories, Lockheed Martin, Northrop Grumman, and Raytheon. Motley Fool Alpha owns shares of Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Matt Koppenheffer owns shares of Abbott Labs and AT&T, but does not own shares of any of the other companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.

Read/Post Comments (10) | Recommend This Article (43)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 11, 2011, at 2:36 PM, howelljsche wrote:

    I am curious to see what the spinoff of Ingalls shipbuilding by Northrup Grumman will do to the share price of NOC.

    Do you have an opinion?

  • Report this Comment On March 11, 2011, at 3:22 PM, TMFKopp wrote:


    Short term I would imagine that it would have a similar impact as other spin-offs, for instance Altria shedding Kraft and then Philip Morris International. That is, the market will readjust the total value of NOC down by the value of Ingalls.

    Longer term, I personally think that'd it'd make NOC more attractive, and to the extent that other investors agree, that could help the stock.

    Of course that's if the Navy doesn't kibosh on the plan (


  • Report this Comment On March 11, 2011, at 7:51 PM, DocG1956 wrote:

    I am not about to buy Astra. A revenue loss of that magnitude. Tell me where they will get that back. I buy dividend stock with the expectation of growth in the share price. I cannot envision that this stock will be moving higher. Someone tell me what would make this dividend play anything but a big risk.


  • Report this Comment On March 12, 2011, at 4:18 PM, onetoein wrote:

    coming late to the party as usual, i was wondering what your take is on going with DRIPs instead of a broker. My tolerance for fees is very low having watched mutual fund profits, such as they were, being nibbled away.

  • Report this Comment On March 13, 2011, at 8:05 AM, GILFIN wrote:

    Hi, I am new to Motley fool and stock investment (That makes a lot !!). I used yahoo finances stock screener to screen values on basis od criterias mentioned by Matt : 1.Forward price-to-earnings ratio below 14; 2.Dividend above 2.5%; 3.Debt-to-equity ratio below 100% (I could not use "Return on unlevered net tangible equity" since I could not find it). Results : 9 matches among wich none of Matt's matches appaered. Can u help me find a stock screener which you (Matt and other Fools) use for picking your stocks. Thx a lot.

  • Report this Comment On March 13, 2011, at 8:19 PM, pmj98765 wrote:

    I am familiar with Marsh. Aon and Willis. Although I like Willis as of right now they are not in the same league as the other 2.

  • Report this Comment On March 14, 2011, at 11:14 PM, TMFKopp wrote:


    If you're using the Yahoo Java screener it's set by default to only return the 25 matches with the highest market cap. Set it to 100+ and you'll get all three that I've mentioned above (or at least you should, I did...).

    As for other quality screeners you can use, there's one right here at The Motley Fool:


  • Report this Comment On March 15, 2011, at 1:51 PM, lisapatric wrote:

    the market will readjust the total value of NOC down by the value of Ingalls.

    <a href="">ooma</a>

  • Report this Comment On March 15, 2011, at 1:57 PM, lisapatric wrote:

    dividend stock with the expectation of growth in the share price.

  • Report this Comment On May 01, 2012, at 10:32 AM, alexrue69 wrote:

    I buy dividend stock with the expectation of growth in the share price.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1456930, ~/Articles/ArticleHandler.aspx, 10/22/2016 7:58:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:03 PM
AZN $30.72 Down -0.28 -0.90%
AstraZeneca CAPS Rating: ****
RTN $136.73 Down -0.58 -0.42%
Raytheon CAPS Rating: ****
WSH.DL $0.00 Down +0.00 +0.00%
Willis Group Holdi… CAPS Rating: **
LMT $230.52 Down -1.31 -0.57%
Lockheed Martin CAPS Rating: ****
MMC $65.03 Down -0.19 -0.29%
Marsh and McLennan CAPS Rating: ****
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****